Vaccinated patients had a 47.6% two-year survival versus 29.2% unvaccinated
In the long human struggle against cancer's most resistant forms, a retrospective study presented at a major nuclear medicine conference in 2026 offers a quietly hopeful signal: men with advanced prostate cancer who had previously received immune-priming vaccines fared meaningfully better when later treated with targeted radiopharmaceutical therapy. The finding, drawn from over a hundred patients at the University of Wisconsin, suggests that the immune system's memory may be a hidden variable in treatment outcomes — one that oncology has only begun to deliberately cultivate. While confirmation through prospective trials remains necessary, the data invite a deeper question about whether the sequence in which we deploy our tools matters as much as the tools themselves.
- Men with metastatic castration-resistant prostate cancer — a diagnosis that often marks the end of effective options — are at the center of findings that could reshape how their disease is treated.
- The gap in outcomes is stark: vaccinated patients achieved PSA50 response rates of nearly 74% versus 56% in unvaccinated peers on the same therapy, and their two-year survival was nearly 20 percentage points higher.
- Immunological analysis revealed that vaccine-primed T cells remained active after radiopharmaceutical treatment, suggesting the two therapies amplify rather than cancel each other.
- Because patients were not randomly assigned — they had joined separate trials at different times — the findings carry the limitations of retrospective design, and the medical community is calling for prospective trials to validate the combination.
- The path forward being charted is a deliberate sequence: prime the immune system first with a prostate cancer vaccine, then deploy targeted radiation therapy when disease progression demands it.
At the 2026 annual meeting of the Society of Nuclear Medicine and Molecular Imaging, a research team from the University of Wisconsin Carbone Cancer Center presented findings that could change how oncologists think about sequencing treatments for advanced prostate cancer. Dr. Bryce Tan and colleagues reviewed outcomes for 109 men treated with 177Lu-PSMA-617 — a radioactive compound that targets prostate-specific membrane antigen — between 2022 and 2025. Among them, 19 had previously enrolled in vaccine trials designed to train the immune system against prostate cancer antigens. A control group of 17 men received standard care without the radiopharmaceutical.
The outcome differences were difficult to dismiss. Vaccinated patients receiving the radiopharmaceutical achieved PSA50 response rates of 73.7%, compared to 55.6% among unvaccinated patients on the same therapy and just 24% in the standard care group. Two-year overall survival reached 47.6% in vaccinated patients versus 29.2% in unvaccinated patients receiving the same treatment — a gap that held up after statistical adjustment for age, disease stage, and prior chemotherapy.
What gave the findings additional weight was an exploratory immunological analysis. Blood samples from both groups were tested for T cell responses to prostate cancer antigens after radiopharmaceutical treatment. Vaccinated patients showed robust immune activity, but so did many unvaccinated patients — suggesting the radiation therapy itself may stimulate immune engagement. The two modalities appeared to work in concert, with prior vaccination amplifying a response the radiopharmaceutical could also initiate on its own.
Both groups received comparable treatment cycles and radiation doses, pointing to immunological preparation — not delivery differences — as the source of the benefit. Tan was careful to note the study's retrospective nature: patients were not randomly assigned, having joined separate trials at separate times. Prospective studies deliberately combining vaccination with radiopharmaceutical therapy will be needed to confirm the effect. Still, the data sketch a plausible and testable strategy — one that asks not just which weapons to deploy against cancer, but in what order to deploy them.
At the 2026 annual meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers presented findings that suggest a simple addition to an existing prostate cancer treatment could meaningfully improve how well it works. The treatment in question—a radioactive compound called 177Lu-PSMA-617—is already used for men with advanced prostate cancer that has stopped responding to hormone therapy. What the new data showed was that men who had previously received a vaccine targeting prostate cancer antigens saw substantially better outcomes when they later received the radiopharmaceutical therapy.
Dr. Bryce Tan and his team at the University of Wisconsin Carbone Cancer Center conducted a retrospective review of 109 men treated with 177Lu-PSMA-617 between January 2022 and January 2025, along with a control group of 17 men who received standard care without the radiopharmaceutical. Among the treated patients, 19 had previously enrolled in clinical trials testing vaccines designed to prime the immune system against prostate-specific antigens—compounds like prostatic acid phosphatase and androgen receptor. The researchers followed all participants through June 2025, tracking their PSA levels (a marker of cancer burden) and survival.
The numbers told a striking story. Among vaccinated patients receiving 177Lu-PSMA-617, nearly three-quarters achieved a PSA response of 50 percent or greater—meaning their cancer markers dropped by half or more. By contrast, only about 56 percent of unvaccinated patients on the same therapy achieved this response, and just 24 percent of those on standard care alone. The survival gap was even more pronounced. At two years, vaccinated patients had a 47.6 percent survival rate compared to 29.2 percent for unvaccinated patients receiving the radiopharmaceutical and 23.5 percent for standard care patients. After adjusting for age, disease stage, prior chemotherapy, and other variables that might skew the results, prior vaccination remained strongly associated with both better PSA response and improved survival.
What made this finding particularly intriguing was not just the outcome difference but the mechanism. The researchers conducted an exploratory immunological analysis on blood samples from vaccinated and unvaccinated patients after they received the radiopharmaceutical therapy. They measured T cell responses to common prostate cancer antigens using a specialized test called IFNγ ELISPOT. The results suggested that the vaccine-primed immune system remained active and responsive even after the radiopharmaceutical treatment—the two approaches appeared to work in concert rather than interfere with each other. Most of the vaccinated patients tested showed robust T cell responses to prostate antigens, as did most of the unvaccinated patients who received the radiopharmaceutical alone, indicating that the radiation therapy itself may trigger immune activation.
The clinical implication is straightforward but significant. Men with metastatic castration-resistant prostate cancer—a diagnosis that typically signals limited remaining options—might benefit from a sequenced approach: first receiving a prostate cancer vaccine to prime their immune system, then later receiving the radiopharmaceutical therapy when their disease warrants it. Both groups received the same median number of treatment cycles and similar cumulative radiation doses, so the benefit appeared to come from the immunological preparation rather than from any difference in how the therapy was delivered.
Tan emphasized that these findings emerged from a retrospective analysis, meaning the patients were not randomly assigned to receive vaccines or not—they had enrolled in separate clinical trials at different times. Prospective studies, in which patients are deliberately assigned to receive vaccination before radiopharmaceutical therapy, would be needed to confirm whether this combination approach truly works better than either treatment alone. Still, the data suggest a plausible path forward: combining two existing tools—one that teaches the immune system to recognize cancer, another that delivers targeted radiation—in a way that might extend survival for men facing one of cancer's most difficult-to-treat forms.
Citas Notables
Prior vaccination against prostate cancer antigens may enhance the clinical efficacy of 177Lu-PSMA-617 therapy in mCRPC, without impairing prostate antigen-specific T cell response— Dr. Bryce Tan, Singapore General Hospital
Prospective studies on the combination therapy of vaccinations and 177Lu-PSMA-617 are warranted— Dr. Bryce Tan
La Conversación del Hearth Otra perspectiva de la historia
Why would a vaccine given months or years before radiation therapy still matter when the therapy is finally administered?
The vaccine doesn't wear off in the way we might think. It trains T cells—immune cells—to recognize specific prostate cancer antigens. Those trained cells persist in the bloodstream. When the radiopharmaceutical arrives and damages cancer cells, it releases those same antigens, and the pre-trained immune system recognizes them immediately and mounts a response. It's like having sentries already posted at the gate.
But the unvaccinated patients who got the radiopharmaceutical also showed T cell responses. Doesn't that suggest the radiation therapy itself is doing the immune priming?
Yes, and that's important. The radiopharmaceutical does trigger immune activation on its own. But the vaccinated patients started with a head start—their immune system was already oriented toward these targets. So when the radiation therapy releases antigens, the response is faster and stronger.
What's the practical barrier to using this combination going forward?
Right now, the vaccines are in clinical trials. They're not yet approved for routine use. So a patient would have to enroll in a trial, complete the vaccine protocol, and then later—sometimes years later—develop advanced disease and become eligible for the radiopharmaceutical. That's a long and uncertain path. The real question is whether we should be designing trials that deliberately combine these two from the start, rather than waiting for patients who happened to receive both.
The survival difference is substantial—47.6 percent versus 29.2 percent at two years. Is that clinically meaningful?
For men with metastatic castration-resistant prostate cancer, absolutely. We're talking about an extra year or more of life for a meaningful fraction of patients. That's not a marginal improvement. But remember, this is a retrospective study. The vaccinated patients might have differed in ways the researchers couldn't fully account for—they might have been healthier, or more engaged with their care, or had better access to treatment.
What would you want to see in the next study?
A prospective trial where men with advanced prostate cancer are randomly assigned to receive the vaccine followed by radiopharmaceutical therapy versus radiopharmaceutical therapy alone. You'd need to follow them long enough to see survival differences, and you'd want to measure immune responses along the way to understand which patients benefit most.